Business
Annovis to Attend the AAIC 2025 with Four Poster Presentations
MALVERN, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced its senior management will attend the Alzheimer’s Association International Conference (AAIC), taking place July 27–31, 2025, in Toronto, Canada. The Company will present four scientific posters highli
About this update from Annovis Bio, Inc.
[{"type":"image","alt":"Annovis Bio Inc.","displaySize":"","headline":null,"caption":"Annovis Bio Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":200,"height":200,"url":"https://media.zenfs.com/en/globenewswire.com/00e49d5ebf66ac512dbaabeac6cdd6eb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/plvHQ2cwqCYZbJvLkT5mUA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTM2MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/00e49d5ebf66ac512dbaabeac6cdd6eb","width":200,"height":200}},"lazy":false},{"type":"text","content":"MALVERN, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced its senior management will attend the Alzheimer’s Association International Conference (AAIC), taking place July 27–31, 2025, in Toronto, Canada. The Company will present four scientific posters highlighting advances of Alzheimer’s clinical program and pharmacokinetic characterization of its lead drug candidate, buntanetap.","length":642,"tagName":"p"},{"type":"text","content":"Presentation details:","length":21,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Poster #1: Design of Phase III study testing buntanetap efficacy in early Alzheimer’s patients based on the insights from previous studies.","length":139,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":139,"olType":false},{"type":"text","content":"Presenter: Cheng Fang, Ph.D., Senior Vice President, Research & Development.","length":80,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Poster #2: A dual 6-month & 18-month prospective, randomized, placebo-controlled, double-blind, pivotal clinical trial investigating efficacy and safety of buntanetap in early Alzheimer's patients.","length":205,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":205,"olType":false},{"type":"text","content":"Presenter: Sarah MacCallum, Director of Clinical Operations.","length":60,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Poster #3: Advancing buntanetap: comparative pharmacokinetic characterization of the original semi-crystalline with the novel crystallin...